In a groundbreaking study poised to reshape neonatal intensive care practices, researchers have explored the nuanced effects of systemic steroids on the survival outcomes of preterm infants vulnerable to bronchopulmonary dysplasia (BPD), with a particular focus on the incidence of cerebral palsy (CP) in this delicate population. The investigation, led by Duncan, Zackula, and Raghuveer, was published recently in the Journal of Perinatology, offering new insights into the complex balance between early intervention and long-term neurodevelopmental health.
Bronchopulmonary dysplasia remains one of the most challenging chronic lung conditions affecting preterm infants, particularly those born before 32 weeks of gestation. Characterized by inflammation and scarring in the lungs, BPD develops in response to both the pathological immaturity of the respiratory system and the mechanical ventilation often required to sustain life. Systemic corticosteroids have been a standard therapeutic option aimed at reducing inflammation and promoting pulmonary function, yet their use stirs controversy due to potential adverse neurodevelopmental consequences.
The central question addressed in this study revolves around whether systemic steroids, administered to mitigate BPD’s pulmonary complications, inadvertently influence survival rates free of cerebral palsy—a severe motor disorder resulting from brain injury or abnormal brain development during early life, disproportionately affecting preterm infants. Using advanced epidemiological methods, the researchers analyzed a comprehensive cohort of preterm neonates, incorporating variables such as gestational age, steroid dosage, timing of administration, and long-term neurological outcomes.
One of the pivotal findings is the delicate timing window in which systemic steroids provide maximum pulmonary benefit without significantly escalating the risk of CP. The study highlights that early initiation of steroids, particularly within the first two weeks of life, can dramatically improve respiratory outcomes, potentially reducing the duration of mechanical ventilation and oxygen dependence. However, this benefit must be judiciously weighed against subtle but measurable increases in neurodevelopmental impairment, raising important clinical dilemmas.
Mechanistically, corticosteroids function by dampening pro-inflammatory cytokine cascades that characterize BPD’s pathogenesis. They inhibit nuclear factor kappa B (NF-κB) and other transcription factors critical in fostering an exaggerated immune response, which if unchecked, damages alveolar development and microvascular structures. Yet, the same steroid-induced suppression of systemic inflammation might interfere with the vulnerable developing brain’s milieu, impairing oligodendrocyte maturation and myelination processes essential for motor and cognitive function.
The researchers employed robust neurodevelopmental assessments, including standardized motor score evaluations and cerebral imaging, to discern subtle manifestations of CP in survivors who had been exposed to systemic steroids. They noted a spectrum of motor deficits, ranging from mild motor delays to more profound cerebral palsy phenotypes with spasticity and coordination impairment. These outcomes underscored the necessity for ongoing surveillance well beyond NICU discharge, as earlier assumptions underestimated the late-emerging sequelae of steroid treatment.
Intriguingly, the study also sheds light on the heterogeneity of steroid responsiveness, influenced by genetic polymorphisms related to corticosteroid receptor sensitivity and drug metabolism. This finding paves the way for personalized medicine approaches, where genetic screening could inform tailored steroid regimens optimizing both pulmonary and neurological outcomes, reducing the one-size-fits-all risk inherent in current protocols.
Beyond pharmacological nuances, environmental factors during NICU stay—including exposure to fluctuating oxygen levels, infection control, and ventilatory strategies—interact synergistically with steroid effects, modulating the risk profile for CP. The authors advocate for integrating steroid therapy within a multicomponent care bundle that minimizes neurotoxicity triggers while maximizing lung protection.
From a public health perspective, these findings carry profound implications. As preterm birth rates continue to rise globally, optimizing interventions that not only save lives but also preserve quality of life remains an urgent priority. The delicate balance between preventing death and ensuring neurodevelopmental integrity demands continuous refinement of neonatal therapies, informed by multidimensional data such as provided by this study.
The medical community is now challenged to revisit existing guidelines on systemic steroid use in preterm infants at risk of BPD. While steroids indisputably improve pulmonary survival metrics, their role in neuroprotection—or conversely, neurotoxicity—calls for nuanced clinical decision-making. The authors emphasize that blanket avoidance or liberal use of steroids is untenable, advocating for stratified approaches that consider individual patient risk profiles and emerging biomarkers predictive of adverse events.
Further research is warranted to explore adjunctive therapies that might mitigate steroid-related neurodevelopmental risks. Interventions such as stem cell therapy, anti-inflammatory biologics targeting specific cytokine pathways, or neuroprotective agents like erythropoietin could hold promise when combined with or substituting systemic steroids. Ongoing clinical trials and translational studies are expected to expand knowledge in this arena over the coming years.
Moreover, this research spotlights the critical need for long-term follow-up registries tracking neurodevelopmental outcomes of preterm infants exposed to various therapies in the neonatal period. Comprehensive data collection will enable healthcare providers to refine risk-benefit analyses and advocate for evidence-based policy changes, ultimately improving survival free of debilitating conditions like cerebral palsy.
The interplay between pulmonary therapy and neurological health exemplifies the complexity of modern neonatology. This study not only advances scientific understanding but also resonates with families and caregivers who confront the harrowing realities of premature birth. It reinforces hope that targeted, science-driven care can alleviate suffering and enhance lifelong potential for the most vulnerable patients.
In summation, Duncan and colleagues’ investigation presents a thorough evaluation of systemic steroids’ dual-edged impact on preterms at risk for BPD, emphasizing the critical balance between survival and neurodevelopmental outcomes. Their meticulous approach offers a roadmap for clinicians, researchers, and policy-makers striving to optimize neonatal interventions in an ethically responsible and medically sound manner.
As neonatal medicine continues to evolve rapidly, this study serves as a clarion call to integrate multidisciplinary perspectives—encompassing pharmacology, genetics, pulmonology, and neurology—in crafting the next generation of therapeutic protocols. Through such holistic understanding, the ultimate goal of enhancing survival without sacrificing neurological integrity becomes an attainable beacon on the horizon.
Subject of Research:
Article Title:
Article References:
Duncan, C.A., Zackula, R.E. & Raghuveer, T.S. Do systemic steroids impact survival free of cerebral palsy in preterm infants at risk for bronchopulmonary dysplasia?. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02475-y
Image Credits: AI Generated
DOI: 05 November 2025
